No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
www.apeloa.comNo one on the platform currently holds 000739.SZ.
No tracked institution reports a position in 000739.SZ as of their last filing.
No one on the platform has traded 000739.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 18.1% | 28.7% | 22.2% | — | — | — |
| Rev. Growth % | -18.8% | 4.4% | ||||
| Profit Margin % | 9.1% | 9.4% | 8.1% | |||
| Free Cash Flow Margin % | 8.7% | 5.0% | 6.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.3B | -1.4% | $0.93 | $0.84–$1.00 | — | 1 |
| 2027 | $11.3B | +9.8% | $1.10 | $0.99–$1.18 | — | 1 |
| 2028 | $12.6B | +11.8% | $1.35 | $1.22–$1.45 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $0.29 | $0.24 | -17.2% |
| 2026-04-20 | $0.19 | $0.22 | +15.8% |
| 2026-03-20 | $0.17 | $0.17 | -2.9% |
| 2025-10-21 | $0.26 | $0.12 | -54.0% |
| 2025-08-19 | $0.32 | $0.27 | -15.6% |
| 2025-04-17 | $0.34 | $0.21 | -38.2% |
| 2025-03-10 | $0.30 | $0.14 | -53.3% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.37 | -1.37% | $25.9B | — |
| 002020.SZZhejiang Jingxin Pharmaceutical Co., Ltd. | $11.46 | -0.43% | $9.9B | — |
| 002317.SZGuangdong Zhongsheng Pharmaceutical Co., Ltd. | $24.80 | -0.36% | $21.1B | — |
| 002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd. | $9.38 | -2.39% | $11.7B | — |
| 002755.SZBeijing Aosaikang Pharmaceutical Co., Ltd. |
| $11.26 |
| -1.23% |
| $10.5B |
| — |
| 600062.SSChina Resources Double-Crane Pharmaceutical Co.,Ltd. | $15.98 | -0.44% | $16.6B | — |
| 600211.SSTibet Rhodiola Pharmaceutical Holding Co. Class A | $36.11 | -3.99% | $11.6B | — |
Source: Financial Modeling Prep · peers by sector/industry